Number of eligible patients: CDEC mentioned the uncertainty in the amount of individuals with moderately serious to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific gurus consulted by CADTH indicated that some people who will be categorised as acquiring delicate or reasonable illness might have a critical bleeding p